https://www.selleckchem.com/pr....oducts/rhps4-nsc7141
Together, our results suggest that PXR could be a biomarker of response to kinase inhibitors in castration-resistant prostate cancers.EGFR mutation analysis in non-small-cell lung cancer (NSCLC) patients is currently standard-of-care. We determined the uptake of EGFR testing, test results and survival of EGFR-mutant NSCLC patients in the Netherlands, with the overall objective to characterize the landscape of clinically actionable EGFR mutations and determine the role and clinical relevance of uncommon and composite EGFR mutatio
Like
Comment
Share
